从幼儿期开始的长期阿托伐他汀-依折麦布-普罗布考三联疗法治疗纯合子家族性高胆固醇血症。

Long-term atorvastatin-ezetimibe-probucol triple therapy for homozygous familial hypercholesterolaemia from early childhood.

作者信息

Lin Minjie, Dai Helong, Zhao Shuiping

机构信息

1Department of Cardiology,Second Xiangya Hospital,Central South University,Changsha,PR China.

2Department of Urological Organ Transplantation,Center of Organ Transplantation,Second Xiangya Hospital,Central South University,Changsha,PR China.

出版信息

Cardiol Young. 2016 Jan;26(1):197-201. doi: 10.1017/S1047951115000591. Epub 2015 Apr 24.

DOI:10.1017/S1047951115000591

PMID:25907359

Abstract

In this observational case report, we share our experience of achieving >40% LDL cholesterol reduction in four Chinese homozygous familial hypercholesterolaemia children below 8 years of age with a triple combination of atorvastatin, probucol, and ezetimibe for >6 years. Within a follow-up duration of 6-13 years, this triple therapy achieved significant reduction of LDL cholesterol as well as an impressive regression of xanthomas in all paediatric cases. All the children remained free from treatment-related adverse responses and cardiovascular events throughout follow-up.

摘要

在这份观察性病例报告中，我们分享了使用阿托伐他汀、普罗布考和依折麦布三联疗法，使4名8岁以下中国纯合子家族性高胆固醇血症儿童的低密度脂蛋白胆固醇降低超过40%，且治疗超过6年的经验。在6至13年的随访期内，这种三联疗法在所有儿科病例中均显著降低了低密度脂蛋白胆固醇，并使黄色瘤令人印象深刻地消退。在整个随访过程中，所有儿童均未出现与治疗相关的不良反应和心血管事件。